| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
64,920,000 |
| Market
Cap: |
1.01(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$13.43 - $23.54 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 31.4 |
| Insider 6 Months : 31.4 |
| Insider 3/6 Months : 63.1 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating cancer therapies. Co.'s products include: Domvanalimab, which is an anti-TIGIT monoclonal antibody designed to promote sustained immune activation and tumor clearance; Etrumadenant, which is a dual A2a/A2b adenosine receptor antagonist, designed to inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes and myeloid cells; AB680, which is a potent and selective small-molecule CD73 inhibitor designed to provide differential benefits relative to monoclonal antibodies; and Zimberelimab, which is Co.'s anti-PD-1 antibody that Co. in-licensed to enable the development of its combination regimens.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
15,238,095 |
15,238,095 |
16,248,095 |
16,248,095 |
| Total Buy Value |
$319,999,995 |
$319,999,995 |
$339,452,595 |
$339,452,595 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
2 |
2 |
| Total Shares Sold |
110,657 |
141,439 |
237,875 |
329,459 |
| Total Sell Value |
$2,164,815 |
$2,731,452 |
$4,652,676 |
$7,003,905 |
| Total People Sold |
2 |
4 |
4 |
6 |
| Total Sell Transactions |
6 |
10 |
16 |
33 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gilead Sciences Inc |
10% Owner |
– – • |
2020-07-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,163,029 |
|
-8% |
|
| Kaneko Yasunori |
Director |
– • – |
2020-06-05 |
4 |
OE |
$7.99 |
$279,650 |
D/D |
35,000 |
38,000 |
|
- |
|
| Rosen Terry J |
Chief Executive Officer |
• • – |
2020-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
289,393 |
|
- |
|
| Ribas Antoni |
Director |
– • – |
2020-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
8,050 |
|
- |
|
| Barker Jason |
See Remarks |
• – – |
2020-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
|
- |
|
| Grossman William |
Chief Medical Officer |
• – – |
2020-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
55,000 |
55,400 |
|
- |
|
| Falberg Kathryn E |
Director |
– • – |
2020-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
83,504 |
|
- |
|
| Jaen Juan C. |
President |
• • – |
2020-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
55,000 |
244,393 |
|
- |
|
| Jarrett Jennifer |
Director |
– • – |
2020-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
103,634 |
|
- |
|
| Machado Clarence Patrick |
Director |
– • – |
2020-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
3,000 |
|
- |
|
| Kaneko Yasunori |
Director |
– • – |
2020-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
3,000 |
|
- |
|
| Lacey David L. |
Director |
– • – |
2020-05-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
35,352 |
|
-53% |
|
| Ribas Antoni |
Director |
– • – |
2019-10-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
8,553 |
|
- |
|
| Ribas Antoni |
Director |
– • – |
2019-10-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,050 |
|
- |
|
| Grossman William |
Chief Medical Officer |
• – – |
2019-10-14 |
4 |
B |
$8.00 |
$2,400 |
D/D |
300 |
400 |
2.66 |
- |
|
| Grossman William |
Chief Medical Officer |
• – – |
2019-10-10 |
4 |
B |
$8.00 |
$800 |
D/D |
100 |
100 |
2.66 |
- |
|
| Jaen Juan C. |
President |
• • – |
2019-06-28 |
4 |
B |
$7.89 |
$38,637 |
I/I |
4,894 |
2,779,240 |
2.66 |
- |
|
| Jaen Juan C. |
President |
• • – |
2019-06-27 |
4 |
B |
$7.44 |
$75,217 |
I/I |
10,106 |
2,774,346 |
2.66 |
- |
|
| Falberg Kathryn E |
Director |
– • – |
2019-06-13 |
4 |
B |
$8.52 |
$110,152 |
I/I |
12,935 |
82,106 |
2.1 |
- |
|
| Falberg Kathryn E |
Director |
– • – |
2019-06-12 |
4 |
B |
$8.49 |
$84,928 |
I/I |
10,000 |
69,171 |
2.1 |
- |
|
| Falberg Kathryn E |
Director |
– • – |
2019-06-11 |
4 |
B |
$7.90 |
$79,000 |
I/I |
10,000 |
59,171 |
2.1 |
- |
|
| Falberg Kathryn E |
Director |
– • – |
2019-06-10 |
4 |
B |
$8.25 |
$82,500 |
I/I |
10,000 |
49,171 |
2.1 |
- |
|
| Falberg Kathryn E |
Director |
– • – |
2019-06-07 |
4 |
B |
$7.99 |
$176,297 |
I/I |
22,065 |
39,171 |
2.1 |
- |
|
| Rosen Terry J |
Chief Executive Officer |
• • – |
2019-06-06 |
4 |
B |
$7.95 |
$18,928 |
I/I |
2,380 |
3,023,139 |
2.58 |
- |
|
| Rosen Terry J |
Chief Executive Officer |
• • – |
2019-06-05 |
4 |
B |
$7.93 |
$153,416 |
I/I |
19,358 |
3,020,759 |
2.66 |
- |
|
207 Records found
|
|
Page 7 of 9 |
|
|
0.08 (0.51%) 
